May 2024
We are very happy to announce a change in the inclusion criteria for the TUBA-WISP II study. From this point forward, also PALB2 PV carriers can be included. The other included pathogenic variants remain the same: BRCA1, BRCA2, RAD51C, RAD51D and BRIP1.
When PALB2 PV carriers are eligible for risk-reducing surgery, they can also participate in the TUBA-WISP II study. We recommend to consider for every individual patient whether or not the benefits of risk-reducing surgery outweigh the risks.
![](https://primary.jwwb.nl/public/g/a/l/temp-rvqgpqwllbcmtjkyhsmx/palb2-engels-high-ccsfk0.png?enable-io=true&enable=upscale&crop=1050%2C600%2Cx0%2Cy0%2Csafe&width=900&height=514)
March 2024
We are very happy to announce that we are currently halfway with inclusions. We have now included 1500 out of the intented 3000 participants!
![](https://primary.jwwb.nl/public/g/a/l/temp-rvqgpqwllbcmtjkyhsmx/green-white-simple-thank-you-banner-landscape-high.png?enable-io=true&enable=upscale&crop=1920%2C960%2Cx0%2Cy0%2Csafe&width=900&height=450)